

Atty. Dkt. No. 018733-0967

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A method for treating an autoimmune disorder, comprising administering to a subject having an autoimmune disorder a therapeutic composition comprising a pharmaceutically acceptable carrier and at least one antibody selected from the group consisting of an anti-CD22 antibody, an anti-CD20 antibody, and an anti-~~CD22~~anti-CD19 antibody.
2. (Original) The method of claim 1, wherein said therapeutic composition is administered parenterally in a dosage of from 20 to 2000 mg per dose.
3. (Original) The method of claim 2, wherein said subject receives said antibody in repeated parenteral dosages.
4. (Original) The method of claim 1, wherein said antibody is selected from the group consisting of subhuman primate antibody, murine monoclonal antibody, chimeric antibody, humanized antibody, and human antibody.
5. (Original) The method of claim 4, wherein said antibody is the murine, chimeric, or humanized LL2 antibody.
6. (Original) The method of claim 1, wherein said therapeutic composition comprises at least two monoclonal antibodies that bind with distinct CD22 epitopes, wherein said CD22 epitopes are selected from the group consisting of epitope A, epitope B, epitope C, epitope D and epitope E.
7. (Original) The method of claim 1, wherein said autoimmune disease is selected from the group consisting acute idiopathic thrombocytopenic purpura, chronic idiopathic thrombocytopenic purpura, dermatomyositis, Sydenham's chorea, myasthenia gravis, systemic lupus erythematosus, lupus nephritis, rheumatic fever, polyglandular syndromes, bullous

Att'y. Dkt. No. 018733-0967

pemphigoid, diabetes mellitus, Henoch-Schonlein purpura, post-streptococcal nephritis, erythema nodosum, Takayasu's arteritis, Addison's disease, rheumatoid arthritis multiple sclerosis, sarcoidosis, ulcerative colitis, erythema multiforme, IgA nephropathy, polyarteritis nodosa, ankylosing spondylitis, Goodpasture's syndrome, thromboangitis obliterans, Sjogren's syndrome, primary biliary cirrhosis, Hashimoto's thyroiditis, thyrotoxicosis, scleroderma, chronic active hepatitis, polymyositis/dermatomyositis, polychondritis, pemphigus vulgaris, Wegener's granulomatosis, membranous nephropathy, amyotrophic lateral sclerosis, tabes dorsalis, giant cell arteritis/polymyalgia, pernicious anemia, rapidly progressive glomerulonephritis and fibrosing alveolitis.

8. (Original) The method of claim 1, further comprising separately administering a secondary therapeutic directed against T-cells, plasma cells, or macrophages or inflammatory cytokines.

9. (Original) The method of claim 8, wherein said secondary therapeutic is administered prior to the administration of said therapeutic composition.

10. (Original) The method of claim 9, wherein said secondary therapeutic is administered concurrently with the administration of said therapeutic composition.

11. (Original) The method of claim 10, wherein said secondary therapeutic is administered after the administration of said therapeutic composition.

12. (Previously Presented) The method of claim 1, wherein said antibody is an anti-CD20 antibody.

13. (Previously Presented) The method of claim 1, wherein said antibody is an anti-CD22 antibody.

14. (Original) The method of claim 1, wherein said antibody is a naked antibody.

Atty. Dkt. No. 018733-0967

15. (Original) The method of claim 14, wherein said antibody is a naked anti-CD22 antibody.

16. (Original) The method of claim 1, further comprising administering a secondary therapeutic directed against T-cells, plasma cells, macrophages, or inflammatory cytokines wherein said secondary therapeutic is conjugated to an anti-B-cell antibody or is separately administered.

17. (Original) The method of claim 1, further comprising administering a secondary therapeutic which is a conjugate of an anti-B-cell antibody with IL-2 or GM-CSF.

18. (Original) The method of claim 16 or 17, wherein said conjugate is used in combination with a naked B-cell antibody.

19. (Original) The method of claim 1, further comprising administering a secondary therapeutic directed against an inflammatory cytokine.

20. (Original) The method of claim 19, wherein said secondary therapeutic is an anti-TNF or anti-IL-1 agent.

21. (Currently Amended) The method of claim 1, comprising administering ~~a naked~~ the at least one anti-CD22, anti-CD19, or anti-CD20, ~~or anti-CD74~~ antibody as a naked antibody or naked antibodies in combination with a conjugate of an anti-CD22, anti-CD19, anti-CD20, or anti-CD74 antibody with a drug, toxin, enzyme, cytokine, hormone, boron compound or therapeutic radionuclide.

22. (Original) The method of claim 21, wherein said naked antibody and said conjugated antibody are directed against the same antigen or epitope.

23. (Original) The method of claim 21, wherein said naked antibody and said conjugated antibody are directed against different antigens or epitopes.

Atty. Dkt. No. 018733-0967

24. (Original) The method of claim 21, wherein said conjugate is a drug conjugate in which the drug is one that acts against B-cells, plasma cells, or T-cells.

25. (Original) The method of claim 21, wherein said conjugate is a drug conjugate in which the drug is one that acts against an inflammatory cytokine.

26. (Original) The method of claim 21, wherein said conjugate comprises an enzyme.

27. (Original) The method of claim 26, wherein said enzyme is an RNase.

28. (Original) The method of claim 1, wherein said therapeutic composition comprises a hybrid antibody which binds more than one B-cell antigen.

29. (Previously Presented) The method of claim 28, wherein said therapeutic composition comprises a hybrid antibody which binds more than one epitope of the same B-cell antigen.

30. (Original) The method of claim 1, wherein said therapeutic composition comprises a bispecific fusion protein, in which at least one arm targets a B-cell and a second arm targets a T-cell, plasma cell or macrophage antigen.

31. (Currently Amended) The method of claim 1, comprising administering a conjugate of an ~~the at least one~~ anti-CD19, anti-CD20, or ~~anti-CD22 or anti-CD74~~ antibody as a conjugate with a drug, toxin, enzyme, cytokine, hormone, boron compound or therapeutic radionuclide.

Atty. Dkt. No. 018733-0967

32. (Currently Amended) The method of claim ~~16~~ 31, wherein said drug is selected from the group consisting of methotrexate, phenyl butyrate, bryostatin, cyclophosphamide, etoposide, bleomycin, doxorubicin, carmustine, vincristine, procarbazine, dexamethasone, leucovorin, prednisone, maytansinoids such as DM1, calicheamicin, rapamycin, leflunomide, FK506, immuran, fludarabine, azathiopine, mycophenolate, and cyclosporin.

33. (Currently Amended) The method of claim ~~16~~ 31, wherein said drug is selected from the group consisting of immuran, methotrexate, and fludarabine.

34. (Original) The method of claim 1, wherein said antibody comprises an arm that is specific for a low-molecular weight hapten and wherein a low-molecular weight hapten with an attached therapeutic agent is administered after the antibody has bound to the B-cell antigen.

35. (Original) The method of claim 34, wherein said hapten is a chelator.

36. (Original) The method of claim 17, wherein said conjugate is used in combination with a naked B-cell antibody.

37. (Previously Presented) A method of treating multiple sclerosis, comprising administering to a subject with multiple sclerosis a therapeutic composition comprising a naked anti-CD20 antibody, a naked anti-CD22 antibody that binds with epitope B of the CD22 antigen, and a cytokine, wherein the two antibodies and the cytokine can be administered concurrently or in any order.

38. (Previously Presented) A method according to claim 36, wherein the cytokine is IFN- β .